Hindustantimes wants to start sending you push notifications. Click allow to subscribe

Covid vaccines for 18+: Maharashtra to give priority to 35-44 age group

Amid limited stock for the third phase for the 18-44 age group and to control crowding at vaccination centres, the Maharashtra government plans to first give the shot to those in the 35-44 age group, with preference to people with comorbidities
By Swapnil Rawal, Mumbai
PUBLISHED ON MAY 08, 2021 12:58 AM IST
HT Image

Amid limited stock for the third phase for the 18-44 age group and to control crowding at vaccination centres, the Maharashtra government plans to first give the shot to those in the 35-44 age group, with preference to people with comorbidities. Chief minister Uddhav Thackeray is expected to take a decision on it, said state health minister Rajesh Tope, adding the inoculation of those in the 18-34 age group would start once adequate doses are available.

Currently, the state is inoculating citizens in the 18-44 age group only at five centres in a district, as the number of doses is limited.

The state started the drive with 300,000 Covishield doses and later purchased 479,000 Covaxin doses. So far, 215,284 citizens in the 18-44 category have been inoculated since May 1.

The move is prompted amid instances of people from urban areas taking an appointment at vaccination centres in rural areas. Tope said such incidents have caused “unrest” among locals in rural areas.

“Till we have abundant supply of vaccines, we will have to make slots as per the age group and comorbidities. If 100% people from the 18-44 category are allowed to go, there can be crowding. We plan to have an age bracket of 35 to 44, with preference to people with comorbidities. I will discuss this with the chief minister,” said Tope.

The state is also in talks with the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund that helped financed vaccine Sputnik V, to purchase doses. “We are trying to get the stock available with them,” Tope told reporters on Friday. He said the state has not got the doses assured by Serum Institute of India for inoculation of the 18-44 category. “The institute had assured us that it would supply additional 350,000 doses, but so far it has not come. For the 18-44 age group, we are going slow as per the availability of 779,000 vaccines. As we get more stock, we will ramp it up.”

With the vaccination of over 700,000 people in the 45+ age group on Wednesday and Thursday, the state is left with a limited number of doses. With under 100,000 doses remaining, the vaccination drive for people over the age of 45 is expected to slow down this weekend, unless doses arrive from the Centre, Tope said. Maharashtra had received 900,000 doses earlier this week from the Centre.

Tope said they are “constantly” following up with the Centre to provide doses of Covishield and Covaxin. Over 400,000 people in the state are due for their second dose of Covaxin. With the Centre not sending Covaxin doses, the state will take a decision on diverting the doses it has purchased for the second dose of people over age 45. The Centre provides vaccines to the states for free. The state has been buying vaccines for those in the 18-44 age group. “Two days ago, we had received 900,000 doses for vaccination of people over 45 years. Of the stock, 800,000 doses have been consumed. We have some thousand vaccines left. We appeal to the Centre to provide vaccines in large quantities, especially Covaxin. Around 400,000 to 500,000 people are due for their second dose of Covaxin. It has to be given within 42 days. If they do not provide in time, the state will divert the Covaxin doses it has purchased. But we are confident that the Centre will provide adequate doses,” Tope said.

The minister reiterated the state is prepared to purchase 120 million doses at one go for the inoculation of 57.1 million population in the 18-44 category as vaccination remains “top priority” of the government. He added the state can ramp up daily vaccinations to 1 million, but the stock is not available.

SHARE THIS ARTICLE ON
This site uses cookies

This site and its partners use technology such as cookies to personalize content and ads and analyse traffic. By using this site you agree to its privacy policy. You can change your mind and revisit your choices at anytime in future.

OPEN APP